Barclays PLC Purchases 223,995 Shares of Arbutus Biopharma Co. (NASDAQ:ABUS)

Barclays PLC boosted its position in Arbutus Biopharma Co. (NASDAQ:ABUS - Free Report) by 466.3% in the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 272,029 shares of the biopharmaceutical company's stock after purchasing an additional 223,995 shares during the period. Barclays PLC owned 0.14% of Arbutus Biopharma worth $1,047,000 at the end of the most recent quarter.

Several other large investors have also recently bought and sold shares of the company. Helen Stephens Group LLC acquired a new stake in Arbutus Biopharma in the third quarter valued at $50,000. XTX Topco Ltd acquired a new stake in shares of Arbutus Biopharma in the second quarter valued at about $53,000. China Universal Asset Management Co. Ltd. raised its position in shares of Arbutus Biopharma by 63.8% during the third quarter. China Universal Asset Management Co. Ltd. now owns 36,309 shares of the biopharmaceutical company's stock worth $140,000 after acquiring an additional 14,138 shares during the last quarter. Intech Investment Management LLC bought a new position in shares of Arbutus Biopharma during the third quarter worth about $142,000. Finally, Zurcher Kantonalbank Zurich Cantonalbank lifted its stake in shares of Arbutus Biopharma by 453.1% in the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 37,503 shares of the biopharmaceutical company's stock worth $144,000 after acquiring an additional 30,723 shares during the period. 43.79% of the stock is currently owned by institutional investors.

Arbutus Biopharma Stock Performance

Shares of Arbutus Biopharma stock traded up $0.08 on Wednesday, reaching $3.26. 509,509 shares of the company's stock were exchanged, compared to its average volume of 829,153. The firm's 50-day moving average is $3.45 and its two-hundred day moving average is $3.72. The company has a market capitalization of $617.74 million, a P/E ratio of -7.58 and a beta of 1.78. Arbutus Biopharma Co. has a 52 week low of $2.21 and a 52 week high of $4.72.

Analysts Set New Price Targets

ABUS has been the subject of several analyst reports. HC Wainwright restated a "buy" rating and set a $5.00 price target on shares of Arbutus Biopharma in a report on Monday, November 18th. JMP Securities increased their price objective on shares of Arbutus Biopharma to $5.00 and gave the stock a "buy" rating in a research report on Wednesday, November 6th. Finally, Chardan Capital restated a "buy" rating and issued a $5.00 target price (up previously from $4.50) on shares of Arbutus Biopharma in a report on Wednesday, November 20th. One investment analyst has rated the stock with a hold rating and four have assigned a buy rating to the company's stock. According to MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $5.50.

About Arbutus Biopharma

Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection in the United States. Its HBV product pipeline consists of imdusiran (AB-729), a proprietary subcutaneously-delivered RNAi therapeutic product candidate that suppresses all HBV antigens, including HBsAg expression.